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Abstract 
 
This review aims to provide a concise yet extensive survey of key short bioactive 
peptide sequences for a range of applications ranging from biomaterials development 
through to peptides with therapeutic uses. The following are considered: cell adhesion 
motifs, structural peptides, cell-penetrating and tumor-homing peptides, antimicrobial 
peptides, peptide hormones, growth factors and matrix metalloprotease substrates, 
neuropeptides, amyloid peptides, antioxidant peptides, peptide affinity tags, 
anticancer peptides and others. This review provides a convenient resource, 
summarizing a broad range of important sequences with great utility both as a 
resource concerning small peptide drugs and also novel biofunctional peptide-based 
materials. 
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1. Introduction 
 
Peptides are remarkable biomolecules with a huge diversity of important roles in vivo. 
Short peptides are generally easy to synthesize by chemical routes or they can be 
obtained recombinantly and are thus attractive agents and targets for therapies and 
diagnostics and the fabrication of bionanomaterials. This review provides a summary 
of short bioactive peptide sequences as a useful “one-stop” reference. Since it is 
obviously not possible to discuss every short peptide sequence with bioactivity that 
has been discovered or synthesized, the focus here is on key sequences. This means 
sequences that have been used in research by many groups for a specific application. 
Most peptides considered in this review are the subject of papers with a few dozen 
citations, although newer key works providing important insights are also discussed. 
Peptides with a broad range of activities ranging from cell adhesion motifs to model 
amyloid peptides are considered here, but it is not possible to list every single short 
peptide sequence that has been studied, hence a threshold has been applied. 
 
This review only deals with short bioactive peptides, short here referring to a peptide 
with approximately 18 or fewer residues. This is a somewhat arbitrary cut-off in some 
senses but it does correspond roughly to the length of peptide that might be 
considered for routine solid phase synthesis. In addition, it ensures that this review 
itself is reasonably compact. Longer peptides such as the peptide hormones glucagon 
(29 residues) or insulin (human insulin has 51 residues) are not discussed here. As a 
general comment, it may be noted that short native linear peptides with ca. 20-100 
residues tend to adopt -helical structures. A linear peptide must have at least a 
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couple of heptad repeats to form an -helical structure. In contrast, many (but by no 
means all) shorter peptide fragments can form -sheet structures (or can be designed 
to do so), as discussed below. Also longer peptides with suitable repetitive domains 
can form -sheet or other secondary structures (polyproline II for example, in the case 
of collagen). Cyclic peptides due to steric constraints tend to adopt turn structures. 
 
This review covers short peptides with bioactivities as summarized in Fig.1. These 
include peptides with roles as cell adhesion motifs, structural peptides (typically 
sequences from extracellular matrix proteins), cell-penetrating and tumor-homing 
peptides, antimicrobial peptides, peptide hormones, growth factors and matrix 
metalloprotease substrates, amyloid peptides, neuropeptides, and other miscellaneous 
natural peptides and peptide tags. The peptides have been discovered through a 
variety of methods which include isolation from natural products, rational screening 
methods such as phage display or peptide library methods or ab initio design or 
“bioinspired” design. Recently, high throughput screening based on protein database 
analysis has been shown to have great scope in the identification of key sequences, for 
example for binding domains to particular substrates. 
 
 
 
Fig.1. Classes of bioactive peptide considered in this review. 
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There is overlap between some sections, in one example antimicrobial peptides often 
show cell-penetrating properties. In another case, combinations of peptides with 
different functionalities may be required for a specific application. For example, 
tissue engineering and the development of protein/peptide-based biomaterials requires 
the presence of multiple motifs, including cell adhesion sequences but also structural 
domains, degradation domains, growth-factor stimulating motifs and others. Excellent 
reviews cover some of the required peptide sequences for biomaterials application in 
tissue engineering, wound healing and regenerative medicine.1-3 Integrin cell adhesion 
motifs such as the classic RGD sequence have been reviewed.4 Reviews are also 
available on cell-penetrating peptides,5-6 antimicrobial peptides7-12 (note though that 
many animal-derived peptides have sequences too long to be considered here13-14),  
peptide hormones,15-19 amyloid,20-28 neuropeptides,29-32 protein tags,33-37 and 
miscellaneous peptides including those with anti-cancer activity. To the best of our 
knowledge, there are no reviews providing a compact and up-to-date brief summary 
of bioactive short peptides. A recent review covers orally absorbed cyclic peptides.38 
Inevitably for such a broad topic, there will be omissions for which we apologize in 
advance. This review is a survey of important and widely-used small bioactive 
peptides, covering the literature from the initial reports on the discovery or design of 
these peptides up to recent examples of their applications. It is not intended to discuss 
every single newly synthesized or discovered small peptide in a review with the scope 
of this one. The intention is to provide a timely and useful summary, providing a 
“toolbox” of known bioactive short peptides for researchers developing new 
biomaterials. 
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In the following, peptide sequences are presented with single letter codes. D-amino 
acids are generally indicated with lower case letters. Peptide termini are generally not 
specified. 
 
Table 1. Summary of Short Bioactive Peptides 
Sequence/Name Source Activity Key references 
RGD(S) Fibronectin Integrin cell 
adhesion motif 
4, 39-44 
Eptifibatide Derived from a 
snake venom 
peptide 
Integrin cell 
adhesion motif 
and 
antithrmobyltic 
45-47 
PHSRN Fibronectin Synergy domain 48 
REDV Fibronectin Integrin cell 
adhesion motif 
49-50 
YIGSR Laminin Integrin cell 
adhesion motif 
51-52 
IKVAV Laminin Integrin cell 
adhesion motif 
53 
DGEA Collagen (type I) Integrin cell 
adhesion motif 
54 
KRSR Designed based 
on consensus 
repeat 
Heparin binding 
and osteoblast 
adhesion 
55-57 
GFOGER/GFPGER Collagen (type I 
and type IV) 
Integrin cell 
adhesion motif 
58-61 
(GAGA)n Silk Structural protein 
62 
(GXY)n (X,Y= residues 
other than G, typically P or 
O, hydroxyproline) 
Collagen Structural protein 63-65 
(VPGXG)n Elastin Structural protein 
66-67 
GGRPSDSYGAPGGGN Resilin Structural protein 68-70 
GYSGGRPGGQDLG Resilin Structural protein 70-71 
YGRKKRRQRRR (TAT 
peptide) 
HIV regulatory 
protein 
Cell-penetrating 
peptide 
72-78 
Penetratin Drosophila 
development 
DNA-binding 
protein 
Cell-penetrating 
peptide 
79-81 
RRWWRF Designed AMP 82 
Surfactin Bacteria AMP 83-85 
Bacitracin Bacteria AMP 86-89 
Polymyxins Bacteria AMPs 90-91 
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Tachyplesins Horseshoe crab AMPs 7, 13, 92 
Protegrins Porcine 
leukocytes 
AMPs 13, 93-94 
Defensins Various 
vertebrates and 
invertebrates 
AMPs 7-8, 13, 94-96 
Bactenecin Bovine 
neutrophils 
AMP 97 
Indolicidin Bovine 
neutrophils 
AMP 7, 11, 13, 98 
Daptomycin Bacteria AMP 99-101 
LPFFD Designed Amyloid  fibril 
disruptor 
102 
Oxytocin Natural hormone Activities related 
to childbirth and 
social bonding 
63, 103 
Vasopressins Natural 
hormones 
Water retention 
Vasoconstriction 
103 
Angiotensins Natural 
hormones 
Vasoconstriction  103-105 
Bradykinin Natural hormone Vasodilator 106-108 
pGHWSYGLRPG Natural hormone Stimulates 
hormone release 
109 
PWpG Natural hormone Stimulates 
hormone release 
110-113 
Somatostatin Natural hormone Endocrine system 
regulator (growth 
hormone 
inhibitor), 
neurotransmitter 
114 
Octreotide Somatostatin 
analogue 
Growth hormone 
inhibitor and 
glucagon and 
insulin inhibitor 
115-116 
Lanreotide Somatostatin 
analogue 
Growth hormone 
inhibitor and 
glucagon and 
insulin inhibitor 
117-119 
Luteinizing hormone 
releasing hormone  
Natural hormone Sperm and 
testosterone 
production 
109, 114 
WMNF Natural hormone Anxiolytic 120 
GNNQQNY Yeast prion 
protein 
Model Amyloid 
Peptide 
121-122 
VQIVYK Tau protein Model Amyloid 
Peptide 
123-125 
(AEAEAKAK)2 DNA-binding 
protein zuotin 
Model Amyloid 126 
RADARADARADARADA Designed Tissue 127-129 
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alternating 
peptide 
engineering 
FF Dipeptide Simplified 
peptide 
nanostructure 
former 
130 
GPQGIAG Collagen type I  MMP substrate 131-132 
Enkephalins Natural opioid 
receptor 
peptides 
Opioid receptor 
peptides. 
Neurotransmitters 
103, 133 
Endomorphins Natural opioid 
receptor 
peptides 
Opiod receptor 
peptides.  
134-135 
Substance P Neurotransmitter Neurotransmitter 
and other roles 
136 
Dalargin Leu-enkephalin 
analogue 
Opioid receptor 
agonist 
137 
Glutathione Natural in most 
organisms 
Antioxidant 138 
AH (carnosine) Muscle and 
brain tissue 
Antioxidant 76, 139-140 
Cyclosporin Soil fungus Immune 
supressant 
141-143 
Oligo(arginine) Synthetic, 
recombinant 
Protein fusion tag 
(also cell-
penetrating and 
antimicrobial) 
34, 144 
Oligo(histidine) Synthetic, 
recombinant 
Protein fusion tag 145-146 
WSHPQFEK (StrepTag II) Synthetic, 
recombinant 
Protein fusion tag 34, 147-148 
EQKLISEEDL (myc tag) Synthetic, 
recombinant 
Protein fusion tag 34, 149  
DYKDDDDK (FlagTag) Designed Protein fusion tag 33, 150 
Bleomycins Bacteria Anti-cancer 
activity 
151-155 
Dolastatin 10 Marine 
organism 
Anti-cancer 
activity 
156-157 
Apicidin Fungal 
metabolite 
Anti-cancer 
activity 
158-160 
Romidepsin Soil bacterium Anti-cancer 
activity 
161-166 
Largazole Cyanobacterium Anti-cancer 
activity 
167-168 
Aspartame (DF-OMe) Synthetic Artificial 
sweetener 
169-170 
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AMP denotes antimicrobial peptide, pG denotes the non-canonical residue 
pyroglutamic acid (Fig.13b). 
 
2. Cell Adhesion Peptides 
The RGD peptide is the minimal unit of a cell adhesive activity domain present in 
adhesion proteins such as fibronectin, fibrinogen and vitronectin, which all contain 
integrin ligands.4l, 39-44 RGD is also presented as an adhesion recognition sequence in 
other proteins including laminin and some types of collagen.171 It is used as a 
canonical cell adhesion motif in a vast range of biomaterials research, interacting with 
the v3 and v5 receptors, and was originally identified as a key factor in 
angiogenesis. The tetrapeptide RGDS, which is also located at the tenth type III 
repeating domain of fibronectin, exhibits high cell adhesion activity via binding to the 
integrin cell-surface receptors.40, 43-44, 172 This motif is, like the shorter RGD variant, 
widely used to encourage cell growth in synthetic biomaterials.173-178 The tetrapeptide 
sequence and more especially the tripeptide RGD subunit are widely employed in the 
development of bionanomaterials for applications in cell growth/differentiation or 
tissue scaffolding.179 The RGDS tetrapeptide has antithrombolytic activity due to the 
inhibition of platelet aggregation resulting from the fibrinogen recognition 
sequence.180-181 The bioactive RGD and RGDS motifs have also been incorporated 
into peptide amphiphiles (PAs).175, 177, 182-187  The RGDS tetrapeptide may have 
enhanced bioactivity compared to RGD due to the additional serine residue.40, 188-191 
The self-assembly of materials containing RGD-peptide sequences has been reviewed 
elsewhere.191 Consideration has been given to why RGD is an effective cell adhesion 
motif, for instance whether the charge pattern anionic R and cationic D separated by 
neutral glycine residue). However, the properties of arginine (such as its ability to 
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form bidentate hydrogen bonds with carboxylic acids (Fig.4) seem vital since the 
analogous KGD sequence is known as a “disintegrin” sequence, for example it is 
found in some snake venom peptide sequences,192-193 instead of RGD which is a potent 
integrin receptor blocker. KGD is a more specific receptor antagonist.192-193 
Disintegrins are short proteins with activity as inhibitors of both platelet adhesion and 
integrin-binding, however the sequences are too long for this class of protein to be 
considered in this review. Actually, covalent attachment of the residues may not be 
essential. For example, it has been shown that co-assembly of Fmoc-dipeptides [Fmoc: 
fluorenylmethyloxycarbonyl] that display R and D separately, i.e. Fmoc-3F-FR and 
Fmoc-3F-FD  [3F-F denotes triply fluorinated phenylalanine], leads to a fibril 
structure which is cytocompatible.194 
 
 
Fig.2 There are multiple cues for cell adhesion with the extracellular matrix. Adapted 
with permission from Ref. 195 Copyright 2010 Annual Reviews.These include 
integrins (labelled , ), cell adhesion motifs Xaa (e.g. RGD), growth factors and 
their receptors (e.g. epidermal growth factor receptor, EGFR) and Notch 
transmembrane cell signaling receptors. Delta is a morphogenic biochemical factor 
involved in ligand clustering. Src is a mechanotransductive tyrosine kinase associated 
with focal adhesions. 
 
Cyclic RGD peptides such as cyclo(RGDfV) (f: D-phenylalanine) are known to have 
superior activity and selectivity compared to linear analogues.196-197 This peptide was 
identified through competitive v3 integrin cell adhesion inhibition studies.196 The 
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cyclic N-methylated compound cyclo(RGDf[N-Me]V) with trade name cilengitide is 
under investigation for the treatment of the brain cancer glioblastoma.17, 197-199 The 
related cyclic heptapeptide eptifibatide (also known as integrilin) also contains an 
RGD mimetic sequence Mpr-HomoArg-GDWPC-NH2 (cyclized via disulfide bridge) 
[Mpr: mercaptopropionic acid, HomoArg: homoarginine].47 It is an important 
antithrombolytic agent as it inhibits platelet aggregation.46 It was derived based on a  
sequence from a snake venom peptide.45, 47 
 
 
It is known that high affinity recognition by the 51 integrin requires a so-called 
synergy peptide PHSRN, a sequence present in fibronectin.48, 200-201 However, it has 
been noted that mixing (equimolar quantities of) peptide amphiphiles presenting 
PHSRN and GRGDSP does not lead to significant synergistic effects on 51 
recognition.202-203 Instead, careful design of a peptide to present these sequences in a 
similar fashion to fibronectin is required (i.e. the spacing between the ligands and 
nature of the spacer need to be considered).202-204 
 
The REDV (and lesser known LDV) sequences are also cell adhesion motifs from 
fibronectin. They bind to the 41 integrin.49-50 REDV sequence bears obvious 
sequence similarity to RGDS. It was noted that endothelial cells such as HUVECs 
(human umbilical vein endothelial cells) adhere to an REDV functionalized substrate 
but not fibroblasts or vascular smooth muscle cells.205-206 The KQAGDV sequence 
also promotes smooth muscle cell adhesion.55, 207-208 
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The YIGSR peptide is a cell adhesion domain from the extracellular matrix protein 
laminin, present in the basement membrane.51-52 Both poly(RGD) and poly(YIGSR) 
have been reported to show anticancer activity, which is enhanced compared to the 
corresponding oligomers, against lung tumors in mice.209 Multimeric YIGSR also 
inhibits angiogenesis and tumor growth of human fibrosarcoma cells in mice.210 The 
IKVAV peptide, also obtained from laminin, promotes cell attachment, spreading and 
neurite outgrowth.53 A peptide amphiphile (PA) incorporating IKVAV shows promise 
in the treatment of spinal cord injuries in a study where cultured cells such as neurons 
were exposed to solutions containing PA fibrils.211-212 A hybrid PA incorporating both 
laminin sequences YIGSR and IKVAV supports the survival of neurons and their 
morphogenesis (dendrite and axon growth) when mixed with collagen to form a 
fibrous scaffold.213 Other laminin cell adhesion recognition sequences such as 
PDSGR (a synergy peptide for YIGSR) have been identified171, 200, 214 but are less 
widely employed.  
 
A minimal sequence DGEA from type I collagen is able to recognize the 21 integrin 
receptor.54 Peptides containing this sequence are able to inhibit adhesion of platelets 
to collagen mediated by 21, but not v1-mediated adhesion of platelets to 
fibronectin or 61-mediated adhesion to laminin.54 For breast adenocarcinoma cells 
which use 21 as a collagen/laminin receptor, adhesion of collagen and laminin was 
inhibited by DGEA-containing peptides. Stem cell (human mesenchymal stem cells, 
hMSC) attachment was compared215 for coatings of PAs incorporating three different 
cell adhesion motifs -  RGDS, DGEA and KRSR. The RGDS-containing PA showed  
the highest initial attachment and subsequent osteogenic differentiation.215 The latter 
is a heparin proteoglycan binding sequence and osteoblast adhesion promotor.55-57 
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The KRSR motif was discovered as a consensus repeat from protein database analysis 
of bone-related adhesion proteins.57 
 
The GFOGER (O: hydroxylproline) domain, originally identified based on the 
sequence GFPGER within collagen I,61 is a high affinity binding site to the integrin 
21 in collagens I and IV and 11 in collagen 1.60 Integrin binding sites to other 
collagens have also been identified.59 Since the 21 integrin receptor is involved in 
osteogenesis, the GFOGER domain has been incorporated into biomaterials designed 
to assist bone repair.216-217  
 
3. Structural Peptides 
Structural peptides can be large molecules, however they are included in this review 
since they comprise repeated short peptide sequences. One very widely studied 
structural peptide is silk. Silk has a semicrystalline structure with crystalline domains 
embedded in an amorphous matrix.62 Silk from the Bombyx mori silk moth can be 
considered to be a multiblock copolymer. The crystalline domains contain repetitive 
(GAGA)n domains forming stacked -sheets as well as GS and GT hydroxyl-
containing dipeptide sequences.62, 218-219 On the other hand, dragline spider silk 
contains polyalanine repeats.62, 220 
 
Collagen is another structural protein based on repetitive peptide sequences. Collagen 
chains form a right-handed triple helical structure. The peptide contains repeating 
GXY triplets where X and Y are often proline and hydroxyproline respectively.63-65 
Elastin is an important extracellular matrix protein with, as its name suggests, elastic 
properties. It is an essential constituent of connective tissues such as skin and 
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ligament. Elastin-like peptides (ELPs) contain (VPGXG)n repeats where X can be any 
amino acid except proline.67, 221 ELPs have attracted great interest since they undergo 
a transition resembling a lower critical solution temperature (LCST), above which the 
polymer chains collapse and phase separation from water occurs.221-222 This can be 
exploited in thermoresponsive release systems for example.223 
 
Resilin is a structural protein found in insect wings, ligaments and other insect and 
arthropod organs. It has elastic properties. Bioactive sequences from the full peptide 
have been identified and used to create elastomeric biomaterials.69  The first key 
resilin sequence identified was GGRPSDSYGAPGGGN, this being presented in 
repetitive form at the N terminus of a protein express by Drosophila melanogaster.68-
70 Another key sequence is GYSGGRPGGQDLG70-71 and others are listed in the 
literature.70 These sequences are essential in conferring elasticity. The tyrosine 
residues in resilin can undergo cross-linking (through radical formation) which has a 
significant impact on its structural and mechanical properties.224-225 
 
4. Cell-Penetrating and Tumor-Homing Peptides 
 
There are a number of mechanisms by which cell-penetrating peptides can enter cells 
as illustrated in Fig.3 involving direct translocation or via various endocytosis 
processes. This subject is reviewed extensively elsewhere.5-6, 226-229 
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Fig.3. Mechanisms for entry of cell-penetrating peptides into a cell. Reproduced with 
permission from Ref. 227. Copyright 2012 Elsevier. 
 
The HIV-1 domain peptide TAT (Trans-Activator of Transcription) is a cell-
penetrating peptide (CPP) widely used as a vehicle for transport of actives (for 
example to deliver peptides conjugated to TAT) into cell nuclei.72-75, 77, 230 It was 
shown to enter HeLa cells when added to culture medium.72-73 This transduction 
domain has high efficiency and is widely used. A shorter TAT peptide core domain 
RKKRRQRR has been used in several studies on cell internalization231 and gene 
delivery.232 Alternative protein transduction domains (PTDs), including those based 
on other viral proteins are discussed elsewhere.75, 233 The penetratin peptide 
RQIKIWFQNRRMKWKK is derived from a DNA-binding protein involved in 
Drosophila fly morphogenesis.79-81 It has an ability to translocate across neuronal 
membranes where it is conveyed to nuclei.79 
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The highly cationic nature of the arginine-rich sequence in TAT peptides is a key to 
its cell-penetration ability since mammalian cells have membranes rich in zwitterionic 
lipids such as phosphocholines (microbial cell membranes in constrast contain anionic 
lipids such as phosphoglycerols). These become polarized in the presence of cationic 
peptides, especially arginine-rich peptides containing guanidinium groups which form 
bidentate bonds with POO- moieties (Fig.4).78 Arginine-rich cell-penetrating peptides 
cause membrane pore formation due to the formation of negative Gaussian curvature 
in the lipid membrane upon interaction with the guanidinium group.12, 234-235 Since 
natural cell-penetrating peptides are often rich in arginine residues, synthetic oligo-
arginines such as octa-arginine have been investigated as vehicles for cellular 
transport.230, 236 Cyclic arginine-rich peptides have also been investigated as CPPs.237-
240 
 
 
Fig.4. Bidentate binding of guanidinium groups with acidic XOO- groups (X = C, P) 
 
Cyclic peptides containing the ACDCRGDCFC sequence (identified from a phage 
display assay of RGD peptides binding to specific integrins including 51, v3, v5 
and m3241) are selective for v integrins and show “tumor-homing” properties when 
injected into cancerous mice.242 Peptides containing the CNGRC sequence were 
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identified by similar phase display assays and also exhibit tumor-homing behavior.242-
243 This peptide contains the cell-adhesive NGR sequence (present in the cell-binding 
region of fibronectin) located from phase display studies of binding to 51 and 
v3.42, 244 The related peptide CGKRK also shows anti-tumor proaptotic properties, 
and potential in the treatment of glioblastoma.245-246 Similarly, within the family of  
C-terminal R/KXXR/K sequence-containing peptides identified by Ruoslahti et al. as 
having tissue penetrating properties, the peptide CRGDK shows tumor-homing 
properties.247-248 The Ruoslahti group also identified the CREKA tumor-homing 
peptide by phage display screening using transgenic breast cancer mice.249 
 
5. Antimicrobial Peptides 
There are several classes of antimicrobial peptides (AMPs). As mentioned in the 
Introduction, many AMPs of animal origin have longer sequences than consistent 
with the focus of this review. Nevertheless a variety of shorter ones are considered in 
this section. One class of short AMP are those rich in arginine residues. Other AMPs 
include those that are rich in tryptophan, proline- rich peptides, or disulfide-bridged 
(-hairpin) peptides.12 Another category, although not mutually exclusive, is 
microbially-derived AMPs with cylic headgroups. Some of these antimicrobial 
peptides are C-terminal amidated13, 94 although this is not explicitly identified herein. 
Some AMPs require the presence of counterions for their activity, e.g. Ca2+ for 
Daptomycin.250 This has led to the idea to create novel AMPs bearing organometallic 
moieties, a strategy to potentially overcome antimicrobial resistance since such units 
are not encountered in natural AMPs.251 
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AMPs act by disrupting bacterial cell membranes, usually mediated by electrostatic 
interactions between peptide cationic residues and anionic lipoteichoic acids and/or 
lipopolysaccharides which form the outer structure of the bacterial membrane. A 
number of detailed mechanisms, for example the “carpet” or “barrel-stave” models 
(Fig.3) have been proposed. In the former case, it is proposed that the peptide coats 
the outer membrane, whereas in the latter, transmembrane pores are formed by 
amphpathic -helical peptides.252 These comprise two faces, with one face 
hydrophobic and the other hydrophilic. These aggregate into pores in membranes with 
the hydrophilic faces on the interior of the pore.After the initial association with the 
membrane surface, AMPs can cause membrane pore formation, or thin the membrane 
or can translocate into the interior. Further details on this can be found in other 
reviews.8, 10-11, 13 It is recognized that many natural AMPs are rich in the cationic 
residues lysine or arginine.12, 253 As mentioned in Section 4, this is also a feature of 
many cell-penetrating peptides and simply reflects the ability of these peptides to 
induce membrane lysis. To be useful therapeutically, the lysis needs to be selective to 
bacterial membranes and not those of eukaryotes. The anti-microbial activity of oligo-
arginine containing-peptides has been examined, although selectivity for bacterial 
membranes with minimal cytotoxicity in humans was not demonstrated.254 
 
Tryptophan has also been identified as an important residue in several series of 
important AMPs including several biologically-derived peptides described in more 
detail below. Model sequences incorporating tryptophan include RRWWRF82 and 
FRWWHR255 (both capped at both termini).  Tryptophan is weakly hydrophobic and 
is believed to undergo cation- interactions with cationic species including ions or 
sidechains of positively charged amino acids.12 
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Short natural AMPs include surfactins, fengycins and iturins (Fig.5).256-257 All are 
lipopeptides with a cyclic peptide headgroup, which enhances stability against 
degradation. Surfactin is a widely studied biosurfactant, and is readily available 
commercially.83 This and other bioactive lipopeptides are attracting attention due to 
their ready production using fermentation methods.256, 258 Bacillus subtilis mainly 
produces three families of lipopeptidic biosurfactant: the surfactins, the fengycins (or 
plipastatins) and the iturins (including mycosubtilin.257 These lipopeptides provide a 
potentially attractive alternative to chemically synthesized surfactants and they also 
have potential applications due to their antimicrobial and antifungal properties.84-85, 
256-257 As well as the afore-mentioned antimicrobial and antifungal activity, these 
compounds also have other potential uses in biomedicine,256, 259 for instance 
exhibiting anti-tumor properties. Some related natural cyclic antimicrobial and 
antifungal lipopeptides are discussed in a recent review on the self-assembly and 
bioactivity of lipopeptides.260  
 
 
(a)                                            (b)
(c)                                            (d)
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Fig.5. Structure of some lipopeptides produced by B. subtilis.260 (a) Surfactin (b) 
Lichenysin, (c) Iturin A, (d) Fengycin/plipastatin A. Adapted with permission from 
Ref. 261 Copyright 2013 Royal Society of Chemistry.As detailed in ref.257, the 
expressed lipopeptides actually comprise a mixture of lipid chain lengths.The bio-
derived materials comprise a mixture of molecules with different lipid chain lengths. 
 
 
The bacitracins are a series86-89 of related cyclic lipopeptides (Fig.5a) with activity 
against Gram-positive bacteria due to their influence on the peptidoglycan synthesis 
in the bacterial cell wall. These compounds were originally derived from B. subtilis 
and B. lichenformis.87 Lichenysins,262-263 pumilacidins264 and the polymyxin B 
peptides (Fig.6b)91 are classes of antimicrobial molecules produced by Bacillus 
licheniformis, Bacillus pumilus and Bacillus polymyxa respectively.260 Lichenysin A 
is a powerful surfactant, and antimicrobial activity against several gram positive and 
gram negative bacteria, although not as great as that observed for surfactin.262 Several 
pumilacidins show antiviral activity against herpes simplex virus as well as anti-ulcer 
activity.264 Polymyxin B (Fig.6b) and polymyxin E (colistin) show antibiotic activity 
against a range of gram-negative bacteria.91 The two molecules are distinguished by 
the substitution of a D-leucine in colistin with a D-phenylalanine in polymyxin B.90 
The mode of action of these lipopeptides has been proposed to be membrane 
disruption due to interaction between the cationic polymyxin and the anionic bacterial 
outer membrane leading to a detergent-like activity.91 A wide range of other cyclic 
depsipeptide (in which one or more amide groups are replaced by the corresponding 
ester goup) and N-methylated peptide (peptoid) antibiotics have been investigated.38, 
265-266 
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Fig.6. Molecular structures of (a) bacitracin A1,
89 polymyxin B1 and B2.
38, 90 
 
The two tachyplesin antimicrobial peptides contain four cysteines forming two di-
sulfide bridges to give a bicyclic peptide (Fig.7). These peptides, originally obtained 
from horseshoe crabs, are highly cationic containing five residues.7, 13, 92 The class of 
protegrin peptides (from porcine leukocytes), protegrin-1 to protegrin-5, have a 
similar bicyclic structure, containing six arginines.13, 93-94 Defensins are longer 
cysteine-rich antimicrobial peptides isolated from a variety of animals.7-8, 13, 94-96   
These peptides are too long to be considered further in this review. Bactenicin with 
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sequence RLCRIVVIRVCR is bridged by a single disulfide bond.7-8, 13, 97 It is 
obtained from bovine neutrophils and is among the shortest bio-derived cationic 
AMPs.267 Many other antimicrobial peptides have been and are being discovered from 
natural sources such as soil (e.g. the newly discovered antibiotic teixobactin268 as well 
as the gramicidins discussed below) or organisms such as amphibians (e.g. 
magainin94, 269) or spiders (e.g. gomesin94, 270). However, these are also not discussed 
in detail here, as the sequences are too long. Summaries of natural antimicrobial 
peptides from plants and animals are available in the literature.8, 10, 13, 94, 271-272 
 
 
 
 
 
 
 
 
 
(a) 
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(b) 
 
 
 
Fig.7. (a) Molecular structure of tachyplesin 1.92 (b) Sequence code with S-S bridge 
location indicated. 
 
The gramicidins are a series of 15-residue peptides active against Gram-positive 
bacteria, being derived from the soil bacterial species Bacillus brevis. The peptides 
have the sequence with alternating L- and D- residues, formyl-XGAlAvVvWlYlWlW-
ethanolamine, where X is V or I and Y is W (gramicidin A),273 F (gramicidin B)89, 274-
275 or Y (gramicidin C).89, 274-275 Gramicidin D is a mixture of related peptides276 and 
Gramicidin S is the cyclic decapeptide  cyclo(VOLfP)2 [O: ornithine].
7 Gramicidins 
are interesting antimicrobial peptides without cationic residues. They form -helix 
dimers which span the lipid bilayer,277-279 causing the formation of selective ion 
KWCFRVCYRGICYRRCR
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channels, rather than causing bacterial cell lysis due to electrostatic binding as in the 
case of the cationic AMPs discussed above.  
 
Among animal-derived host defense peptides, those with short sequences include 
indolicidin and bactenicin. Indolicidin, which is cow-derived (from bovine 
neutrophils), has the sequence ILPWKWPWWPWRR7, 11, 13, 98 and can be seen to be 
tryptophan-rich. Peptides rich in this residue can have antimicrobial properties as well 
as arginine-rich ones,12 and in fact indolicidin is stated to be have the highest 
tryptophan content of any “protein”.98, 280 A number of studies also point to anti-viral 
activity of indolicidin.10 Derivatives of the wasp venom peptide mastoparan281 with 
sequence INLKALAALAKKIL are being investigated as potential antimicrobial 
agents despite the toxicity of the parent peptide to mammalian cells.282 The derivative 
mastoparan-X INWKGIAAMAKKLL has had its conformation in solution 
determined by NMR283 which reveals it to be surely one of the shortest -helix 
forming peptides (Fig.8). 
 
Fig.8. Structure from solution NMR of Mastoparan-X (pdb: 2CZP).283 
 
Helical peptides containing the KLAK sequence have been shown to possess selective 
and potent antimicrobial activity with low mammalian cytotoxicity. 284 Antimicrobial 
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activity was demonstrated for both Gram-negative E. coli and Gram-positive S. 
aureus.284 The (klakkla)2 peptide (in its D-amino acid form to reduce proteolysis) was 
conjugated to ‘tumour homing’ sequences cyclo(CNGRC) or double cyclic 
ACDCRGDCFC to create anti-cancer peptides which showed anti-cancer activity in 
mice.285 
 
Daptomycin is a potent AMP which is a cyclic branched 13-residue peptide produced 
by the Gram-positive bacterium Streptomyces roseosporous.99-100 It is also known 
under the tradename Cubicin and is used as an antibiotic to treat serious infections 
caused by Gram-positive bacteria.101, 250 It is effective against infections where 
antimicrobial resistance is a problem, including methicillin-resistant Staphylococcus 
aureus (MRSA)100 and vancomycin-resistant Enterococci.101, 286   There are two 
katanosin cyclic depsipeptides with antimicrobial activity. Katanosin B is also known 
as lysobactin (originally isolated from a strain of Lysobacter)287-289 and katanosin A 
has a similar structure with a V7I substitution.289 Both are potent AMPs with activity 
against Gram-positive bacteria such as Staphylococci.287-289  
  
The echinocandins are a class of cyclic peptides with antifungal activity. They operate 
by blocking cell wall glucan synthesis.290-292 Anidulafungin, caspofungin and 
micafungin are all examples of echinocandins (Fig.9).38, 260 The most widely known is 
caspofungin, marketed as a drug by Merck and Co. The antifungal activity of this 
class of compound is due to the interaction of lipopeptide molecules with the 
insoluble polysaccharide component of the cell wall of fungal cells, specifically in the 
due to the inhibition of the synthesis of glucans.290 The interactions of echinocandins 
with Candida fungi such as C. albicans has been particularly well studied.290-291 
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Fig.9. Structures of caspofungin, anidulafungin and micafungin. Adapted from ref.38  
 
Beauvericin (Fig.10) is a symmetric cylic depsipeptide (strictly, peptoid as the amides 
are N-methylated) with antifungal and insecticide properties.293-294 It was originally 
isolated from a fungus,295 and is structurally related to the enniatin family of 
cyclohexa-depsipeptides.296  
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Fig.10. Molecular structure of beauvericin.295 
 
6. Peptide Hormones 
 
There are many peptide hormones with diverse biological activities in signaling and 
other response pathways.15-16, 18-19 Several classes of peptide hormones have 
sequences too long to be considered further here but there are nonetheless several of 
them with short sequences and important biological functions. 
 
Oxytocin is a member of a series of related peptide hormones which are nonapeptides 
with an intramolecular disulfide bond which produces a small cyclic ring (Fig.11a).63 
Oxytocin is known as the love hormone, due to putative activity in social bonding.297-
300 It is used medically to facilitate childbirth (it simulates uterine contractions)63, 103 
and milk secretion.103 The vasopressins are a series of peptide hormones with similar 
structures to oxytocin, i.e. they are 9-residue peptides containing a disulfide bond 
which creates a cyclic region within the molecule.63 Vasopressins act as 
vasoconstrictors and are thus targets for blood pressure modulation.63 They also 
stimulate water resorption by the kidneys and are thus antidiuretic agents.63 Arginine 
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vasopressin, with sequence CYFQNCPRG stabilized by an intramolecular disulfide 
bridge between the two cysteine residues, is the basis for the antidiuretic (and 
anticoagulant) desmopressin which has the arginine vasopressin sequence but with the 
first C residue deamidated and with D-Arg instead of L-Arg (Fig.11b).301 
 
 
 
Fig.11. (a) Molecular structures of (a) Oxytocin, (b) Desmopressin. 
 
The angiotensins are a series of four linear peptide hormones. The first, angiotensin I 
is obtained by cleavage of the angiotensinogen protein by renin.103-105 Angiotensin I 
contains 10 residues NRVYIHPFHL, angiotensin II is derived from this by cleavage 
of the two C-terminal residues,103-105, 302 angiotensin III is the heptapeptide RVYIHPF 
and angiotensin IV is the core hexapeptide VYIHPF.104, 302 Angiotensin II has the 
important bioactivity of vasoconstriction and blood pressure increase.104 It is 
produced from Angiotensin I by angiotensin-converting enzyme (ACE) and hence 
ACE inhibitors are therapeutic agents for blood pressure reduction and cardiovascular 
disease.303-304 Angiotensin II receptor antagonists are also important therapeutic 
agents. Angiotensin II has an identified role in inflammation and it can regulate 
growth factors and cytokines.305 
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Bradykinin, with the sequence RPPGFSPFR, is a short peptide hormone with activity 
in blood vessel dilation (vasodilation), hence in reduction of blood pressure.106 It is 
also associated with inflammatory pain.107-108 The angiotensin converting 
enzyme (ACE) inhibitors increase bradykinin production.106 
 
Somatostatin, also known as growth hormone-inhibiting hormone, is a 14-residue 
cyclic peptide (Fig.12).306 It plays an important role in cell proliferation (via inhibition 
of the secretion of growth factors and cytokines) 307 and neurotransmission.308  
 
 
Fig.12. Molecular structure of somatostatin. 
 
Octreotide (tradename Sandostatin) is a cyclic octapeptide (Fig.12) that mimics the 
activity of somatostatin.115-116 It was designed to have enhanced in vivo stability due 
to the inclusion of D-amino acids as well as other modifications. The D-configuration 
of tryptophan fosters a bioactive conformation, based on a -turn centered on wK. 
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Octreotide is a powerful growth hormone inhibitor which can be used to treat the 
growth hormone disorder acromegaly for example.115, 309 Lanreotide is another long-
acting analogue of somatostatin. Both octreotide and lanreotide act on the same 
receptors as somatostatin (G protein-coupled somatostatin receptors) and both are 
inhibitors of insulin and glucagon.119 Lanreotide is a homologue of octreotide 
(Fig.13).117-119 It self-assembles into nanotubes in aqueous solution.310-313 
 
 
Fig.13. Molecular structures of octreotide115 and lanreotide.119 
 
Luteinizing hormone releasing hormone (LHRH) also known as gonadotropin-
releasing hormone (GnRH) is a decapeptide with sequence pGHWSYGLRPG (pG: 
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pyroglutamic acid, Fig. 14b).114 This peptide, produced in the hypothalamus, binds to 
the LHRH receptor, and triggers the release of luteinizing hormone (LH) and the 
follicle stimulating hormone (FSH), which are responsible for the production of 
testosterone and sperm, respectively.109 Another tropic (i.e. having endocrine glands 
as target) peptide hormone produced in the hypothalamus is TRH, thyrotropin-
releasing hormone (Fig.14a).110 This tripeptide (L-proline-L-histidyl-L-pyroglutamyl 
amide or 5-oxo-L-prolyl-L-histidyl-L-prolinamide) also contains the pyroglutamyl 
residue. It has the commercial name protirelin and is used in the diagnosis of thyroid 
disorders among other applications.111-113  
 
 
Fig.14. Molecular structure of (a) thyrotropin-releasing hormone, (b) pyroglutamic 
acid. 
 
Gastrin stimulates the secretion of gastric acid in the stomach. Gastrin peptide 
hormones have a common C-terminal motif. There are several variants (some too long 
to fit within the scope of this review) such as minigastrin or gastrin-14, 
WLEEEEEAYGWMNF.314 Tetragastrin (WMNF) is discussed further in Section 9. 
 
7. Tissue Engineering and Biomaterials Development 
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Cell adhesion motifs which are key sequences in the design of biomaterials for tissue 
engineering are discussed in Section 3. Here, several additional components that are 
desirable in materials which can remodel in response to cellular cues are considered.  
 
Growth factors are important in tissue engineering and wound healing. A list of 
growth factors involved in different processes (angiogenesis, wound healing etc) is 
available.315 Growth factors are large native proteins, however short peptide substrates 
for growth factors have been identified. The peptide YRSRKYSSWYVALKR, taken 
from a sequence FGF(106-120) is an activator of the basic fibroblast growth factor 
(FGF-2 or bFGF) receptor.316 
 
The GPQGIAG sequence is a substrate for MMP-1 and MMP-2 (which cleave 
between G and I) and has been used in the development of many biomaterials for 
tissue engineering applications.1, 132, 317-318 An excellent review on MMP substrate 
sequences is available.132 Other agents involved in tissue remodeling include the 
plasminogen enzymes. These degrade blood clots in the process of thrombolysis, i.e. 
they degrade fibril in the process of fibrinolysis. A list of tetrapeptide plasminogen 
activator cleavage sites is available.2 All have N terminal arginine residues and at 
least one other polar residue (serine, threonine or arginine). Elastase is a protease 
enzyme which degrades elastin (Section 3). It acts on substrates containing oligo-
alanine repeats.319-320 The serine protease -chymotrypsin cleaves selectively 
following aromatic residues,321 e.g. in KLVFF-based peptide conjugates.322-323 The 
substrate specificity for other serine proteases has been investigated.324-325 Other 
substrates for degradation used in biomaterials for tissue engineering include the 
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APGL collagenase degradation sequence and the VRN substrate for plasmin mediated 
degradation.55 
 
Heparin-binding peptide sequences are also an important component of biomaterials 
for applications in wound healing since heparin is a powerful anticoagulant. Heparin-
binding peptide sequences include FAKLAARLYRKA from Antithrombin III,2, 326 
and others.69 
  
The “RAD16” RADARADARADARADA peptide (and similar variants) became a 
commercial product (PuraMatrix) with applications in tissue engineering as hydrogels 
of this peptide can support the growth of various types of cell.127-129 
 
8. Amyloid Peptides 
 
Amyloid peptides form -sheet fibril structures. Those discussed here are either 
simple alternating sequences or fragment peptides from disease-related amyloid 
peptides or proteins. 
 
Alternating sequences such as GAGA in silk discussed above favour -sheet 
formation. The presence of alternating hydrophobic and hydrophilic residues further 
enhances amyloid aggregation propensity. For example, the peptide EAK16  
(AEAEAKAK)2 was among the first to be studied which is consistent with this design 
rule, with the additional feature that the charge of the hydrophilic residue changes in a 
sequenced fashion.126 This peptide is present in the yeast protein zuotin. The Zhang 
group also studied related peptides such as KFE12, FKFEFKFEFKFE, with 
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alternating charged residues.327-328 This peptide forms gels in suitable salt solutions.328 
As mentioned above, the “RAD16” RADARADARADARADA peptide is an amyloid 
former.127-129 The structural and rheological properties of similar octapeptides (which 
can form -sheet hydrogels) with alternating residues such as FEFEFKFK have been 
investigated.329-332 The influence of the amino acid pattern on the self-assembly motif 
of this class of octapeptide has been examined.333 
 
Due to the intense research interest in amyloid formation of relevance to protein 
misfolding diseases including Alzheimer’s, Parkinson’s, type II diabetes etc.,25 much 
work has been done using model amyloid forming peptides. The following describes a 
few key model amyloid peptides and is not a full list since so many have been 
investigated. Some well-known sequences now have X-ray crystal structures 
determined, and a selection of the more widely used model peptides are discussed in 
the following.28, 125 
 
One widely studied amyloid-forming peptide is GNNQQNY from the yeast prion 
protein Sup35. Among many studies of its amyloid properties can be highlighted fibre 
diffraction studies121 and a crystal structure determination which reveals the formation 
of a steric zipper (Fig.15) in which the side chains are intercalated within the cross- 
structure.122, 125 Other examples of steric zippers, which exclude water from the 
interior of amyloid fibrils, include phenylalanine zippers.334-335 
 
The VQIVYK sequence from tau (residues 306-311) forms -sheet filaments,123 with 
a cross- structure.124, 336 A crystal structure determination is available, which reveals 
a steric zipper arrangement.125, 337  
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Fig. 15. Amyloid steric zipper structures from x-ray crystallography on 
GNNQQNY.125 Carbon atoms are purple or white, nitrogen atoms are blue and 
oxygen atoms are red. The yellow circles indicate water molecules. 
 
Deposits of human islet amyloid polypeptide (hIAPP) also known as amylin are found 
in the pancreas of people with type II diabetes.338-340 The peptide NFGAIL from 
hIAPP has been extensively used as a model amyloid-forming peptide,341 following 
its identification as a minimal -sheet forming sequence.342 Importantly, a crystal 
structure of NNFGAIL is available and this shows unusual features for an amyloid 
peptide, specifically a pronounced bend around the G residue and a lack of side chain 
interpenetration as in a typical steric zipper arrangement.343 
 
The peptides KLVFF and KLVFFAE from the Amyloid  (A) peptide (residues 16-
20 and 16-22 respectively) are believed to be a core aggregating sequences.344-346 
Indeed, peptides incorporating this fragment can bind the full length peptide and 
prevent fibrillization.347 Fragments based on KLVFF have been designed to inhibit 
A40 and A42 fibrillization. Rational design principles based on the knowledge of 
the pentapeptide binding sequence led to the preparation of LPFFD,102 now known as 
the -sheet breaker peptide. This peptide incorporates proline, known to hinder -
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sheet aggregation and was found to reduce amyloid deposition in vivo (rat model) and 
to disassemble pre-formed fibrils in vitro.102  
 
The FF dipeptide is a fragment of KLVFF (and of course other peptides) and it was 
suggested that its -stacking has an important role in amyloid formation.348 FF has 
remarkable self-assembly properties, although it does not form strictly amyloid -
sheet structures.349-350 This peptide forms nanotubes in aqueous solution130, 349 and in 
organic solvents it is possible to prepare vesicles or nanoparticles from it. Capped FF 
can form fibrils or nanotubes depending on the nature of the capping group,351-352 and 
vertical arrays of nanotubes can be prepared from FF (with different capping groups) 
by spreading a film from HFIP.353 The aggregation of peptides through aromatic 
stacking interactions can be enhanced by additional of bulky aromatic units such as 
Boc [tert-butoxycarbonyl] or Fmoc.354-355 Boc-FF can form nanospheres in water as a 
transient in the nanotube formation process,356 or stable nanospheres with very high 
stiffness in organic solvent.357 The uncapped FF dipeptide can also form nanospheres 
(“quantum dots”) in organic solvents.358 Strategies other than addition of bulky 
aromatic substituents have been used to modulate the self-assembly of FF. One is to 
incorporate halogenated phenylalanine,359-361 or other substituted phenylalanine 
derivatives.361 Other approaches include changing chirality, i.e. substitution with the 
D-amino acid,362 or N-terminal derivatization with other aromatic groups. 354-355, 363-364 
 
Computational methods have recently been used to assess the aggregation propensity 
of all of the 203 = 8000 tripeptides.365 After the computational screening, candidates 
were synthesized and assessed for hydrogelation ability based on -sheet fibril 
network formation.  
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9. Neuropeptides, Antioxidants and Immune-Related Peptides 
 
There are two enkephalin peptides Met-enkephalin YGGFM and Leu-enkephalin 
YGGFL which are endogenous ligands for -opioid receptors in the brain.103, 133 
Dalargin with sequence YaGFLR (a: D-alanine) is a Leu-enkephalin analogue with 
specificity for  opioid receptors.366 Dalargin is usually excluded from the brain 
however lipidation leads to a self-assembled fibril structure, which is reported to both 
reduce degradation in plasma and enables transport across the blood-brain barrier.367 
The endomorphin tetrapeptides have high selectivity and affinity for the -opioid 
receptors.134 Two endomorphin peptides were isolated from brain extracts. 
Endomorphin-1 has the sequence YPWF and endomorphin-2 has the sequence YPFF. 
These peptides are of interest for the further development of pain relief therapies.  
However, it has to be noted that the direct application of these peptides in analgesia 
was demonstrated in a rodent model by i.c.v. (intracerebroventricular) administration. 
135 Peripheral administration of these peptides is ineffective as they are too easily 
degraded, appropriately modified versions may be designed to circumvent this. 
 
Substance P is the undecapeptide RPKPQQFFGLM which acts as a neurotransmitter 
and is involved in pain and analgesia.368-369 It is a member of the tachykinin family of 
neuropeptides which have the common  C-terminus FXGLM136 where X is a 
hydrophobic residue. 
 
Another class of neuroactive peptides are the tryptophan-containing non-ionizable 
opioid peptides such as the naturally occurring (fungus derived) tetrapeptide 
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cyclo[Phe-D-Pro-Phe-Trp], known as CJ-15208.38, 370 This peptide is an orally-
available antinociceptive (it blocks pain stimuli by sensory neurons). It is able to cross 
the blood-brain barrier and reach opioid receptors.370  
 
A series of fragments of the cholecysotokinin peptide are found naturally. 
Cholecystokinin is a gastric peptide, identified as a 33-residue peptide in porcine 
intestine extracts.371 It causes the release of digestive enzymes and acts as a satiety 
signal.372-373 Cholecystokinin octapeptide (CCK-8) has the sequence 
NY(SO3H)MGWMNF (i.e. it contains a sulfated tyrosine residue).
371 Cholecystokinin 
tetrapeptide (CCK-4), also known as tetragastrin, is a peptide fragment derived from 
the larger peptide hormone cholecystokin and has the sequence WMNF. It is an 
anxiolytic and is used to induce panic attacks in studies of anxiety.120 The C terminal 
sequence in these peptides is common to the gastrin peptide hormones as mentioned 
in Section 6. 
 
Glutathione is tripeptide (L--glutamyl-L-cysteinylglycine, H-isoGlu-Cys-Gly-OH) 
denoted GSH, in which there is a gamma peptide link between the glutamic acid side 
chain and cysteine. It is an antioxidant, the thiol group serving as a reducing agent in 
vivo, disrupting disulfide bonds in proteins to yield free cysteine groups.138, 374 It is 
involved in many biological processes including metabolism, protein and DNA 
synthesis and protection of cells.138 
 
 
The dipeptide L-carnosine (-alanine-histidine, AH) has a range of biological 
activities.76, 140, 375-376 In particular it has antioxidant properties for carbohydrates 
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(anti-glycation)377-378 and lipids (anti-lipoxidation).139 The presence of thealanine 
(AH) residue is implicated in these roles, since it can react directly with oxidized 
carbohydrates and lipids.379  The histidine (H) residue is able to bind to transition 
metal ions. Histidine-containing dipeptides such as L-carnosine  are present in the 
mammalian brain within neuroglia and certain types of neurons.380 Carnosine is 
present in muscle and nerve tissue, as well as the brain.76, 140, 375-376 Carnosine has 
been proposed as a treatment for Alzheimer’s disease,380  and it has also been shown 
to delay senescence of cultured cells,381 which has been ascribed to the antioxidant 
properties of the peptide.378 
 
Thymopentin, also known as TP-5, is a pentapeptide fragment (RLNVY) 
corresponding to residues 32 to 36 of human thymopoetin (a.k.a. lamina-associated 
polypeptide 2).382-383 Thymopentin is an immunostimulant, used for example in the 
treatment of dermatitis.383 Many other medical applications involving 
immunomodulation have been summarized.384 Splenopentin with sequence RLGVY 
is a related immunomodulation peptide.384 Cycloinopeptide is a cyclic nonapeptide 
cyclo-(Pro-Pro-Phe-Phe-Leu-Ile-Ile-Leu-Val) extracted from linseed oil385  with 
activity as an immunosuppressant.386 
 
Cyclosporin or cyclosporine (Fig.16) is a cyclic 11-residue peptide/peptoid hybrid 
with sequence  cyclo[AbuSar(N(Me)L)V(N(Me)L)Aa(N(Me)L)(N(Me)L)(N(Me)V)-
(N(Me)Bmt(E))].143, 387 Peptoids are N-substituted analogues of peptides, and here Sar 
denotes sarcosine, N-methylglycine, Abu denotes aminobutric acid and Bmt(E) 
denotes (E)-but-2-enyl threonine. Cyclosporin is a powerful immunosuppressant, 
working on T-lymphocytes.141-142, 387 It also displays antifungal and anti-inflammatory 
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properties. It is an extract from soil fungus and is synthesized by a nonribosomal 
synthetase.142 
 
Fig.16. Molecular structure of cyclosporin. 
 
10. Protein Tags 
 
Recombinant production of proteins is becoming a ubiquitous technology. Peptide 
tags enable isolation via affinity chromatography of expressed proteins cleaved at 
defined positions (Fig.17). Short peptide cleavage sequences have advantages 
compared to longer tags in minimizing the effect on the processing and conformation 
of the expressed protein. 
 (a)      (b) 
 
 
42 
 
Fig.17. (a) Affinity chromatography purification of recombinant proteins tagged with 
an affinity peptide domain. (b) Cleavage done on column or after elution.388 
 
 
The oligo-or poly-histidine tag (e.g. hexa-histidine), developed by researchers at 
Roche,145-146 is widely used in the affinity purification of expressed recombinant 
proteins.389 The protein to be labelled is engineered to incorporate N- or C-terminal 
histidine repeats. A common system employs a hexahistidine tag along with a metal 
chelate among which the nitrilotriacetic acid (NTA)/Ni2+ system is widely used. Since 
nickel ions are hexa-coordinated and four electrons are used in binding to NTA, two 
electrons are available to bind hexahistidine tags. This interaction has high affinity 
and selectivity.390-392 Other oligopeptides including oligo(arginine) (developed in 
1984144), oligo(aspartic acid) and oligo(phenylalanine) have also been used as fusion 
tags.33 Some of these sequences can adversely influence the tertiary structure of 
proteins to which they are attached.34 
 
The Strep-tag II peptide (WSHPQFEK) is an affinity sequence for use in streptavidin 
or modified streptavidin columns.34, 147-148 The myc or c-myc tag (derived from a 
transcription factor regulator gene) corresponds to peptide EQKLISEEDL.34, 149 Use 
of this tag is based on a known anti-c-myc antibody used as an immunochemical agent 
in cell biology.393 
 
A range of other peptide tags, including commercially licensed technologies, has been 
developed including FlagTag (sequence DYKDDDDK) which incorporates a 
cleavage site for enterokinases (a class of digestive enzyme).33, 150 It is used in 
immunoaffinity chromatography. The Spytag peptide with sequence 
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AHIVMVDAYKPTK394 is designed to bind to the Spycatcher protein via amide bond 
formation.395 
 
Derivatives of the cyclic peptide phalloidin (Fig.18) are used as fluorescent tags. 
Phalloidin is a bicyclic heptapeptide, originally isolated from the death cap 
mushroom.396 It is used in fluorescent stains in cell viability studies because it binds 
to (and stabilizes) actin (in its filamentous form),396-397 which is an essential 
component of the cytoskeleton. 
 
 
 
 
 
 
 
Fig.18. Molecular structure of phalloidin. 
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Lists of other fusion tags for recombinant protein production are available with detail 
on the purification systems and the advantages and disadvantages of particular 
systems.33-35, 37 
 
11. Anti-Cancer Peptides 
 
Anticancer “tumor-homing” peptides have been discussed in Section 4. Here several 
types of cyclic peptide with anticancer activity are discussed. 
 
Bleomycins are important anti-cancer agents. The molecules are peptide derivatives 
(Fig.19), being glycosylated peptide-polyketides containing two thiazolines resulting 
from cyclization of cysteine residues.151-155 The bleomycins are non-ribosomal 
peptides produced by the bacterium Streptomyces verticillus.151 They act by cleaving 
DNA strands.154, 398 Bleomycins have been classed as “metalloantibiotics” because 
they were originally discovered to be antibiotics and their activity (binding and 
cleaving DNA molecules) depends on the presence of ions (especially Fe2+).89 
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Fig.19. Molecular structure of bleomycin A2.
154 
 
Dolastatin 10 (Fig.20) is a short peptide containing five residues with an interesting 
selection of non-proteogenic amino acids.156-157 This peptide, originally isolated from 
a marine mollusk, has potential anticancer activity, as it has an antimitotic activity, 
inhibiting tubulin polymerization.157 Dolastatin 10 is one example from a diverse 
range of marine natural products with anti-cancer properties resulting from 
microtubule growth inhibition,17, 399-400 such as hemiasterlins which are short linear 
peptide derivatives obtained from a marine sponge.401 
 
 
Fig.20. Molecular structure of dolastatin 10. 
 
Apicidin (Fig.21a) is a cyclic tetrapeptide which is a histone deacetylase inhibitor 
(HDAC).158-160 It was isolated as a fungal metabolite.402 It has potential anticancer 
activity158-160 and acts against protozoan parasites such as Plasmodium (malaria 
infective agent),402 among other applications. Chlamydocin is a related cyclic 
tetrapeptide403 obtained from origins as a fungal natural product.38, 404 It is reported to 
inhibit the growth of tumor cells.405-406 Romidepsin (Fig.21b) is a bicyclic 
depsipeptide (isolated from a soil bacterium161) which is also a histone deacetylase 
inhibitor with pronounced anticancer activity against several types of lymphoma.162-
166 Largazole (Fig.20c) also belongs to the class of cyclic depsipeptide natural 
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products with HDAC anticancer activity.167-168 A variety of other, less well studied 
cyclic peptides with anticancer activity are covered in a recent review.38 
 
 
 
Fig.21. Molecular structures of (a) apicidin,402-403 (b) romidepsin,38, 161 (c) 
largazole.168, 407 
 
12. Miscellaneous Peptides 
 
Protein-protein interactions can occur through recognition of short peptide sequences. 
This has been particularly extensively studied for signaling protein complexes such as 
the Src-homology domains SH2 and SH3.408-409 SH2 and SH3 domains regulate the 
activity of Src tyrosine kinases.  SH2 domains recognize phosphorylated tyrosines in 
specific sequences (see e.g. ref.410). SH3 is a proline-recognition domain which has 
affinity for particular proline sequences such as the consensus motif PXXP.410-412 
Peptides have also been designed to inhibit protein interactions.413 As these proteins 
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involve recognition of sequences within larger proteins, and not short peptides per se, 
this fascinating subject is not considered further here. 
 
The artificial sweetener aspartame is the dipeptide ester DF-OMe.169, 414 Since it 
contains phenylalanine, products containing this peptide are labelled as such to alert 
those suffering from the inherited condition phenylketonuria in which phenylalanine 
metabolism is disrupted. For this and other reasons, the safety of aspartame has been 
investigated in considerable detail.170, 415  
 
A range of peptides have been obtained by screening methods that bind to specific 
inorganic materials, nanoparticles, metals and metal oxides etc. The peptides are of 
interest for peptide functionalization of nanoparticles (for diagnostic or therapeutic 
applications for example), heavy metal remediation, templated synthesis etc. These 
sequences tend to be rather specific to individual studies or a particular application, 
and are not considered further here. Metal ions are also proposed to play important 
roles in the progression of amyloidosis for example of Amyloid .345 Peptides may be 
designed to mimic larger metalloproteins.416 Reviews on the topic of peptides binding 
to inorganic materials/peptide immobilization on inorganic materials are available.417-
418 
 
Another important area where small peptides have promise is the field of artificial 
enzyme where the aim is to create an active hydrophobic pocket mimicking that of a 
folded protein, but using a short peptide. Short histidine-bearing peptides have 
attracted particular attention in the development of peptide-based catalysis. For 
example, the tripeptide Hff is a thermoreversible hydrogelator which is able to 
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catalyse the hydrolysis of an ester.419 Similarly, Fmoc-FFH self-assembles into 
nanotubes and is able to catalyse ester hydrolysis.420 An FF peptide with N-terminal 
ferrocene unit is able to form oil-in-water nanoemulsions and has redox activity.421 In 
another example, the tripeptide glutathione (section 9) is able to form iron-sulfur 
clusters in the presence of UV light, this mimicking the active site of ferrodoxins.422 
The self-assembly of small peptides into defined nanostructures may itself lead to 
enhanced activity in catalysis, since the peptide is presented at high density. In one 
example, (EF)n and (FE)n lipopeptides capped with N-terminal proline are able to 
catalyse an aldol reaction when aggregated (as fibrils) but this does not occur with 
unaggreated homologues (with much shorter C-terminal alkyl units).423 
 
13. Conclusions and Discussion 
 
Combining different functionalities into a peptide sequence is not as straightforward 
as just linking peptide sequences in a linear fashion due to the multiplicity of 
intermolecular interactions at play including electrostatic forces, van der Waals 
forces, hydrogen bonding, aromatic stacking interactions etc. This is exemplified by 
the discussion in Section 3 about RGD and the synergy PHSRN domain. A defined 
spacing (of amino acids non-functional for integrin binding in this case) between 
these two motifs is needed as a minimal element of a functional conjugate. In other 
cases the design may need more than control of just spacing, or it may simply not be 
possible to create a conjugate when the functional domains are incompatible or 
antagonistic. Lipidation is a strategy to create assemblies of a hydrophilic peptide 
domain presented at high density on the surface of nanofibrils, which can exhibit 
enhanced bioactivity compared to the unconjugated peptide.424 
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Computational screening (e.g. the impressive first analysis of aggregation propensity 
of all tripeptides365) is a powerful method which could be developed to screen other 
properties of di- and tri-peptides but it is of limited use for larger peptides where 
unfortunately as yet, ad hoc design rules, serendipity or bioinspiration are required to 
discover novel short peptides with interesting functionality. This review has given an 
overview of some examples. Unfortunately an overarching set of principles able to 
account for why a particular peptide has optimal or excellent desired activity are 
unlikely ever to be available since the parameter space is so vast (not just due to the 
20n hypothetical sequences from the 20 proteinogenic amino acids but all the other 
variables associated with aggregation including solution conditions etc) and the 
number of applications is so large. This is, in part, what makes this such a fascinating 
research field. In particular cases, design rules are available. For instance it is now 
well established that lysis-causing antimicrobial peptides require cationic arginine 
residues in their sequence, whilst ion channel forming cyclic peptides have an 
alternating D/L amino acid design.425 In other cases, such as amyloid peptides, tools 
based on (peptide/amino acid) property databases are available (e.g. WALTZ, 
Zyggregator426 or TANGO427-428 aggregation predictors) to predict aggregation 
propensity however this often only provides post hoc rationalization. 
 
There are many promising directions in the application of novel peptides in fields 
such as tissue engineering and biomaterials development, and the creation of enzyme 
mimics. Some examples of research to date in these fields have been provided but 
there is great scope for further development. Of course, there is also immense interest 
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in small peptide, peptide-based and peptide-inspired therapeutics for a range of 
conditions and this field is likely to see exciting discoveries in the near future. 
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